Economic evaluation of a single-pill triple antihypertensive therapy with XXXX , @entity3591 , and @entity918 against its dual components.

@entity917 @entity1 @entity101 @entity918 @entity3006 @entity3591
UNASSIGNED: The aim of this study was to compare the cost-utility of the first available single-pill triple combination antihypertensive therapy containing @entity917 (V), @entity3591 (A) and @entity918 (H), with each of the same components dual combinations in @entity1 with moderate to severe @entity101 . A Markov model with eight health states was constructed. The short-term effect of antihypertensive treatment on blood pressure was extrapolated through the Hellenic SCORE and Framingham risk equations, estimating the long-term survival and quality-adjusted life-years (QALYs) saved. Costs and outcomes were evaluated over lifetime, divided into annual cycles and discounted at 3.0  % with 2013 as reference year. The analysis was conducted by the Greek third-party-payer perspective. The triple combination treatment cost was estimated at    16,525 compared to    15,480 for V/A,    14,125 for V/H and    11,690 for A/H. The QALYs saved with the triple combination were 12.76 vs. 12.64, 12.61 and 12.38 for double combinations respectively. The incremental cost-effectiveness ratio of the triple combination versus V/A and A/H was far lower than the Greek @entity3006 per capita (   8,690/QALY and    12,695/QALY, respectively) and really close for V/H (   16,192/QALY), suggesting V/A/H combination to be cost-effective. Extensive sensitivity analyses confirmed the robustness of the results. The probability that the triple combination is cost effective was more than 90  % at a willingness-to-pay threshold of    18,000/QALY. This is the first study to evaluate the cost-utility of a single-pill triple combination. The single-pill V/A/H therapy is a cost-effective antihypertensive choice for the treatment of moderate to severe @entity101 , compared to its dual components.
